Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Increased GLASSIA Infusion Rate in Healthy Volunteers
NCT01651351Phase 4Completed
- Sponsor
- Takeda
- Start
- Jul 2012
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Takeda. Primary endpoint: Number of Infusions Associated With a Reduction in Infusion Rate or Discontinuation of Infusion Due to an Adverse Event at Day 15. Started Jul 2012; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT01651351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01651351.